Clinical Trials

Dyslipidemia

Displaying 2 studies

Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk Scottsdale/Phoenix, AZ

The primary hypothesis is that additional LDL-C lowering with Evolocumab (AMG 145) when used in addition to other treatment for dyslipidemia is well tolerated and decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization in subjects with clinically evident cardiovascular disease.
A Study to Improve the Use of Genetic Testing in Disease Prevention and Clinical Care and to Further Understand Types of Genetic Differences that May Cause Disease Scottsdale/Phoenix, AZ

The purpose of this study is to form processes to get findings from targeted gene sequencing that can be acted on using two common actionable genetic disorders–familial hyperlipidemia and familial colorectal cancer.